Cancer Research on Prevention and Treatment    2022, Vol. 49 Issue (06) : 522-527     DOI: 10.3971/j.issn.1000-8578.2022.21.1456
Advances in Treatment of Brain Metastasis from Lung Cancer
SUN Junzhao, CHENG Gang, ZHANG Jianning
Department of Neurosurgery, Chinese PLA General Hospital, Beijing 100853, China
Download: PDF(3602 KB)   ( 62 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Lung cancer is the malignant tumor with the highest incidence and mortality in China, and is prone to brain metastasis in the process of disease development, which seriously affects the quality of life and survival of patients. The treatment methods for brain metastasis of lung cancer include surgery, chemotherapy, whole brain radiotherapy, stereotactic radiosurgery, molecular targeted therapy, immunotherapy, antiangiogenesis therapy, etc. It’s one of the research hotspots to choose reasonable and effective treatment schemes for different patients. This paper reviews the research progress in the treatment of brain metastasis from lung cancer, to provide reference for selecting more reasonable clinical treatment for the patients.
Keywords Lung cancer      Brain metastasis      Whole brain radiotherapy      Stereotactic radiosurgery      Targeted therapy      Immunotherapy      Antiangiogenesis therapy     
ZTFLH:  R734.2  
Issue Date: 15 June 2022
 Cite this article:   
SUN Junzhao,CHENG Gang,ZHANG Jianning. Advances in Treatment of Brain Metastasis from Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 522-527.
E-mail this article
E-mail Alert
Articles by authors
SUN Junzhao
ZHANG Jianning
[1] Hubbs JL, Boyd JA, Hollis D, et al. Factors associated with the
development of brain metastases: analysis of 975 patients with
early stage non-small cell lung cancer[J]. Cancer, 2010, 11 6(21):
[2] S?rensen JB, Hansen HH, Hansen M, et al. Brain metastases
in adenocarcinoma of the lung: frequency, risk groups, and
prognosis[J]. J Clin Oncol, 1988, 6(9): 1474-1480.
[3] Villano JL, Durbin EB, Normandeau C, et al. Incidence of brain
metastasis at initial presentation of lung cancer[J]. Neuro Oncol,
2015, 17(1): 122-128.
[4] Rosenfelder N, Brada M. Integrated treatment of brain
metastases[J]. Curr Opin Oncol, 2019, 31(6): 501-507.
[5] Nahed BV, Alvarez-Breckenridge C, Brastianos PK, et al. Congress
of Neurological Surgeons Systematic Review and Evidence-Based
Guidelines on the Role of Surgery in the Management of Adults
With Metastatic Brain Tumors[J]. Neurosurgery, 2019, 84(3):
[6] Ahluwalia M, Barnett GH, Deng D, et al. Laser ablation after
stereotactic radiosurgery: a multicenter prospective study in
patients with metastatic brain tumors and radiation necrosis[J]. J
Neurosurg, 2018, 130(3): 804-811 .
[7] Tsao MN, Xu W, Wong RK, et al. Whole brain radiotherapy for
the treatment of newly diagnosed multiple brain metastases[J].
Cochrane Database Syst Rev, 2018, 1(1): CD003869.
[8] Rapp SR, Case LD, Peiffer A, et al. Donepezil for Irradiated Brain
Tumor Survivors: A Phase Ⅲ Randomized Placebo-Controlled
Clinical Trial[J]. J Clin Oncol, 2015, 33(15): 1653-1659.
[9] Giuseppe ZR, Silvia C, Eleonora F, et al. Hippocampal-sparing
radiotherapy and neurocognitive impairment: A systematic
literature review[J]. J Cancer Res Ther, 2020, 16(6): 1215-1222.
[10] Starkweather CK, Choi BD, Alvarez-Breckenridge C, et al. Initial
Approach to the Patient with Multiple Newly Diagnosed Brain
Metastases[J]. Neurosurg Clin N Am, 2020, 31(4): 505-513.
[11 ] Mahajan A, Ahmed S, McAleer MF, et al. Post-operative
stereotactic radiosurgery versus observation for completely
resected brain metastases: a single-centre, randomised, controlled,
phase 3 trial[J]. Lancet Oncol, 2017, 18(8): 1040-1048.
[12] Kayama T, Sato S, Sakurada K, et al. Effects of Surgery With
Salvage Stereotactic Radiosurgery Versus Surgery With Whole-
Brain Radiation Therapy in Patients With One to Four Brain
Metastases (JCOG0504): A Phase Ⅲ, Noninferiority, Randomized
Controlled Trial[J]. J Clin Oncol, 2018, JCO2018786186.
[13] Routman DM, Yan E, Vora S, et al. Preoperative Stereotactic
Radiosurgery for Brain Metastases[J]. Front Neurol, 2018, 9: 959.
[14] Hughes RT, s AH, McTyre ER, et al. Initial SRS for Patients
With 5 to 1 5 Brain Metastases: Results of a Multi-Institutional Experience[J]. Int J Radiat Oncol Biol Phys, 2019, 1 04(5):
[15] Hirshman BR, Wilson B, Ali MA, et al. Superior Prognostic Value
of Cumulative Intracranial Tumor Volume Relative to Largest
Intracranial Tumor Volume for Stereotactic Radiosurgery-Treated
Brain Metastasis Patients[J]. Neurosurgery, 2018, 82(4): 473-480.
[16] Traylor JI, Habib A, Patel R, et al. Fractionated stereotactic
radiotherapy for local control of resected brain metastases[J]. J
Neurooncol, 2019, 144(2): 343-350.
[17] Kotecha R, Damico N, Miller JA, et al. Three or More Courses of
Stereotactic Radiosurgery for Patients with Multiply Recurrent
Brain Metastases[J]. Neurosurgery, 2017, 80(6): 871-879.
[18] Boire A, Brastianos PK, Garzia L, et al. Brain metastasis[J]. Nat
Rev Cancer, 2020, 20(1): 4-11 .
[19] Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated
EGFR-Mutated Advanced Non-Small-Cell Lung Cancer[J]. N
Engl J Med, 2018, 378(2): 11 3-125.
[20] Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall
Survival with Osimertinib in Untreated, EGFR-Mutated Advanced
NSCLC[J]. N Engl J Med, 2020, 382(1): 41-50.
[21] Solomon BJ, Cappuzzo F, Felip E, et al. Intracranial efficacy of
crizotinib versus chemotherapy in patients with advanced ALKpositive
non-small-cell lung cancer: results from PROFILE
1014[J]. J Clin Oncol, 2016, 34(24): 2858-2865.
[22] Peters S, Camidge DR, Shaw AT, et al. Alectinib versus Crizotinib
in Untreated ALK-Positive Non-Small-Cell Lung Cancer[J]. N
Engl J Med, 2017, 377(9): 829-838.
[23] Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus Crizotinib
in ALK-Positive Non-Small-Cell Lung Cancer[J]. N Engl J Med,
379(21): 2027-2039.
[24] Shaw AT, Bauer TM, de Marinis F, et al. First-Line Lorlatinib or
Crizotinib in Advanced ALK-Positive Lung Cancer[J]. N Engl J
Med, 2020, 383(21): 2018-2029.
[25] Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell
lung cancer with ALK or ROS1 rearrangement: an international,
multicentre, open-label, single-arm first-in-man phase 1 trial[J].
Lancet Oncol, 2017, 18(12): 1590-1599.
[26] Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of
three phase 1-2 trials[J]. Lancet Oncol, 2020, 21(2): 261-270.
[27] Takada K, Toyokawa G, Shoji F, et al. The Significance of the
PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant
Double Swords as Predictive and Prognostic Markers[J]. Clin
Lung Cancer, 2018, 19(2): 120-129.
[28] Gadgeel S, Rodríguez-Abreu D, Speranza G, et al. Updated
Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus
Pemetrexed and Platinum for Previously Untreated Metastatic
Nonsquamous Non-Small-Cell Lung Cancer[J]. J Clin Oncol,
2020, 38(14): 1505-1517.
[29] Passaro A, Attili I, de Marinis F. CheckMate 9LA: broadening
treatment options for patients with non-small-cell lung cancer[J].
Lancet Oncol, 2021, 22(2): 157-159.
[30] Besse B, Le Moulec S, Mazières J, et al. Bevacizumab in patients
with nonsquamous non-small cell lung cancer and asymptomatic,
untreated brain metastases(BRAIN): a nonrandomized, phase II
study[J]. Clin Cancer Res, 2015, 21(8): 1896-1903.
[31] Gubens MA, Chuang JC, Akerley W, et al. A pooled analysis of
advanced nonsquamous non-small cell lung cancer patients with
stable treated brain metastases in two phase Ⅱ trials receiving
bevacizumab and pemetrexed as second - line therapy[J]. J Thorac
Dis, 2018, 10(1): 219-227.
[32] Uprety D. Clinical utility of ramucirumab in non-small-cell lung
cancer[J]. Biologics, 2019, 13: 133-137.
[33] Jiang S, Liang H, Liu Z, et al. The Impact of Anlotinib on Brain
Metastases of Non-Small Cell Lung Cancer: Post Hoc Analysis
of a Phase Ⅲ Randomized Control Trial (ALTER0303)[J].
Oncologist, 2020, 25(5): e870-e874.
[34] Yomo S, Serizawa T, Yamamoto M, et al. The impact of EGFRTKI
use on clinical outcomes of lung adenocarcinoma patients
with brain metastases after gamma knife radiosurgery: a
propensity score-matched analysis based on extended JLGK0901 dataset (JLGK0901-EGFR-TKI)[J]. J NeuroOncol, 2019, 1 45(1):
[35] Zhuang H, Tao L, Wang X, et al. Tyrosine kinase inhibitor
resistance increased the risk of cerebral radiation necrosis after
stereotactic radiosurgery in brain metastases of non-smallcell
lung cancer: a multiinstitutional retrospective case-control
study[J]. Front Oncol, 2020, 10: 12.
[36] Borius PY, Régis J, Carpentier A, et al. Safety of radiosurgery
concurrent with systemic therapy (chemotherapy, targeted
therapy, and/or immunotherapy) in brain metastases: a systematic
review[J]. Cancer Metastasis Rev, 2021, 40(1): 341-354.
[37] Johung KL, Yeh N, Desai NB, et al. Extended survival and
prognostic factors for patients with ALK-rearranged non–smallcell
lung cancer and brain metastasis[J]. J Clin Oncol, 2016,
34(2): 123-129.
[38] Cho A, Untersteiner H, Hirschmann D, et al. Gamma Knife
Radiosurgery for Brain Metastases in Non-Small Cell Lung
Cancer Patients Treated with Immunotherapy or Targeted
Therapy[J]. Cancers (Basel), 2020, 12(12): 3668.
[39] Kotecha R, Kim JM, Miller JA, et al. The impact of sequencing
PD-1/PD-L1 inhibitors and stereotactic radiosurgery for patients
with brain metastasis[J]. Neuro Oncol, 2019, 21(8): 1060-1068.
Related articles from Frontiers Journals
[1] ZHU Xiaoli, XU Lu. Research Progress of Markers Related to Early Diagnosis of Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 875-879.
[2] YANG Junyuan, CAI Hongbing. Countermeasures and Mechanisms of Drug Resistance in Immunotherapy for Cervical Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 886-892.
[3] TIAN Zhen, ZHU Neng, LI Zilin, CHEN Yongzhong, LI Hong, ZHANG Xinhua. Effect of PEG-rhG-CSF in Preventing Chemotherapy-induced Neutropenia in Locally Advanced Non-small Cell Lung Cancer Patients at Nutritional Risk[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 904-907.
[4] ZHAN Na, XU Wei, ZENG Zhi, DONG Liling. Diagnosis Value of Tumor-associated Auto-antibodies Combined with Low-dose Spiral Computed Tomography in Early Lung Cancer Screening[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 908-912.
[5] YIN Zhucheng, LIANG Xinjun. Research Progress on Combined Immunotherapy for Microsatellite Stable Colorectal Cancer#br#[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 977-981.
[6] CAO Guangwen. Theoretical Update of Cancer Evo-Dev and Its Role in Targeted Immunotherapy for Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 747-755.
[7] KANG Yikun, YUAN Peng. Advances in Treatment of Triple Negative Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 812-819.
[8] YIN Zhucheng, LIANG Xinjun. Research Progress on Hyperthermia and Anti-Tumor Immunity[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 827-831.
[9] XIA Siyu, ZHAO Zitong, LI Li. Correlation Between STK11 Gene Mutation and Immunotherapy of Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 850-854.
[10] CHEN Yarui, WANG Jiangtao, GUAN Quanlin, JI Wei, JIAO Fuzhi. Research Progress of Antibody-drug Conjugates in Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 855-860.
[11] CHEN Weichang, SHI Tongguo, ZHU Jinghan, SUN Linqing, LI Juntao. Progress on Immunotherapy of Gastrointestinal Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 639-643.
[12] JIN Tongtong, ZHOU Chuan, WANG Chao, DA Zijian, ZHOU Fenghai, . Research Hotspots and Frontiers of Immunotherapy for Prostate Cancer: A Visual Analysis[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 667-674.
[13] WU Wei, JING Doudou, CAO Li, PU Feifei, SHAO Zengwu. Current Status and Prospects of Immunotherapy for Osteosarcoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 721-726.
[14] CHEN Bojin, HU Xingyi, ZHAO Jingwen, ZHENG Aihong. Current Status of Immunotherapy in Neoadjuvant Therapy for Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 727-732.
[15] WAN Xiaoying, ZHOU Songwen. Research Progress of M2-type Tumor-associated Macrophages in Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 733-737.
Full text